- Home
- IBRX vs PDO Comparison
IBRX vs PDO Comparison
Compare IBRX & PDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PDO
- Stock Information
- Founded
- IBRX 2014
- PDO 2020
- Country
- IBRX United States
- PDO United States
- Employees
- IBRX N/A
- PDO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PDO Trusts Except Educational Religious and Charitable
- Sector
- IBRX Health Care
- PDO Finance
- Exchange
- IBRX Nasdaq
- PDO Nasdaq
- Market Cap
- IBRX 1.9B
- PDO 1.6B
- IPO Year
- IBRX N/A
- PDO N/A
- Fundamental
- Price
- IBRX $3.42
- PDO $13.88
- Analyst Decision
- IBRX Strong Buy
- PDO
- Analyst Count
- IBRX 3
- PDO 0
- Target Price
- IBRX $13.58
- PDO N/A
- AVG Volume (30 Days)
- IBRX 6.0M
- PDO 520.0K
- Earning Date
- IBRX 03-18-2025
- PDO 01-01-0001
- Dividend Yield
- IBRX N/A
- PDO 11.80%
- EPS Growth
- IBRX N/A
- PDO N/A
- EPS
- IBRX N/A
- PDO N/A
- Revenue
- IBRX $7,332,000.00
- PDO N/A
- Revenue This Year
- IBRX $2,359.81
- PDO N/A
- Revenue Next Year
- IBRX $808.10
- PDO N/A
- P/E Ratio
- IBRX N/A
- PDO N/A
- Revenue Growth
- IBRX 1218.71
- PDO N/A
- 52 Week Low
- IBRX $2.28
- PDO $10.65
- 52 Week High
- IBRX $10.53
- PDO $13.31
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- PDO 55.67
- Support Level
- IBRX $3.35
- PDO $13.71
- Resistance Level
- IBRX $4.27
- PDO $13.94
- Average True Range (ATR)
- IBRX 0.31
- PDO 0.09
- MACD
- IBRX 0.04
- PDO -0.02
- Stochastic Oscillator
- IBRX 29.17
- PDO 48.53
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.